Treatment with histamine-type 2 receptor antagonists and omeprazole increase the risk of diarrhoea in neonatal foals treated in intensive care units
Article first published online: 7 FEB 2012
© 2012 EVJ Ltd
Equine Veterinary Journal
Special Issue: Equine Perinatology
Volume 44, Issue Supplement s41, pages 80–86, February 2012
How to Cite
FURR, M., COHEN, N. D., AXON, J. E., SANCHEZ, L. C., PANTALEON, L., HAGGETT, E., CAMPBELL, R. and TENNENT-BROWN, B. (2012), Treatment with histamine-type 2 receptor antagonists and omeprazole increase the risk of diarrhoea in neonatal foals treated in intensive care units. Equine Veterinary Journal, 44: 80–86. doi: 10.1111/j.2042-3306.2011.00499.x
- Issue published online: 7 FEB 2012
- Article first published online: 7 FEB 2012
- Received: 07.03.11; Accepted: 20.08.11
- acid-suppressive drugs
Reasons for performing study: The use of anti-ulcer medication in the neonatal intensive care unit (ICU) is common due to the concern for development of catastrophic gastric ulcer disease. In man, however, the use of acid-suppressive medication has been shown in some studies to be a substantial risk factor for the development of Clostridium difficile-associated diarrhoea (CDAD), bacteraemia and neonatal sepsis.
Objective: The purpose of the study reported herein is to evaluate the influence of anti-ulcer medications on the development of diarrhoea in the neonatal foal.
Hypothesis: The use of anti-ulcer medication does not alter the incidence of diarrhoea in foals treated in an ICU.
Methods: The records of 1710 foals from 6 different equine hospitals were examined and the use of anti-ulcer drugs was recorded. The presence of in-hospital acquired diarrhoea, CDAD, Clostridium perfringens-associated diarrhoea, neonatal sepsis and salmonellosis were documented. In addition, the presence of gastric ulceration, duration of hospital stay and short-term outcome were examined.
Results: The use of anti-ulcer medications increased the odds of in-hospital diarrhoea by 2.0 (95% CI 1.4–2.9; P<0.0001), relative to the use of no anti-ulcer medication. There was no significant association of anti-ulcer medication with CDAD (P = 0.3189) (OR 2.0; 95% CI 0.4–9.5). Further, results indicated that decreased prevalence of gastric ulceration was not associated with use of anti-ulcer drugs among foals in the study for which these data were known (P = 0.5522).
Conclusions: Use of anti-ulcer drugs increases the odds of developing diarrhoea, and may not reduce the incidence of gastric ulceration in hospitalised equine neonates.
Potential relevance: The use of anti-ulcer drugs in neonatal foals being treated in a hospital setting should be carefully evaluated on an individual basis to determine if such use is warranted.